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Summary
Dysfunction of the immune system underlies a plethora of human dis-
eases, requiring the development of immunomodulatory therapeutic inter-
vention. To date, most strategies employed have been focusing on the
modification of T lymphocytes, and although remarkable improvement
has been obtained, results often fall short of the intended outcome.
Recent cutting-edge technologies have highlighted macrophages as poten-
tial targets for disease control. Macrophages play central roles in develop-
ment, homeostasis and host defence, and their dysfunction and
dysregulation have been implicated in the onset and pathogenesis of mul-
tiple disorders including cancer, neurodegeneration, autoimmunity and
metabolic diseases. Recent advancements have led to a greater under-
standing of macrophage origin, diversity and function, in both health and
disease. Over the last few years, a variety of strategies targeting macro-
phages have been developed and these open new therapeutic opportuni-
ties. Here, we review the progress in macrophage reprogramming in
various disorders and discuss the potential implications and challenges for
macrophage-targeted approaches in human disease.
Keywords: macrophages; polarization; reprogramming.
Introduction
Historically considered as broad-range phagocytes playing
a relatively ‘passive’ role within the immune system,
macrophages (MФ) have since benefited from more recent
intensive characterization. Present in almost every tissue,
MФ have been divided into two broad subclasses: those
derived from an embryonic progenitor and those from
adult monocytes. Many tissue-resident MФ have a prena-
tal origin (yolk sac- or fetal liver-derived), their develop-
ment is dependent on at least one essential tissue-specific
transcription factor, and they maintain themselves by
Abbreviations: AAV, adeno-associated virus; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; BBB, blood–brain bar-
rier; BMDM, bone marrow-derived macrophage; CIA, collagen-induced arthritis; CNS, central nervous system; DC, dendritic cell;
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DNA 3; IFN-c, interferon-gamma; IL, interleukin; IRF5, interferon regulatory factor 5; KC, Kupffer cell; LXR-a, liver X recep-
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self-renewal, while others are recruited from the peripheral
monocyte pool.1 The origins and replenishment of MФ
populations have been the subject of numerous reviews2-6
and are not the focus of the present one. Tissue-resident
MФ are the predominant type of MФ present during
steady state and are thought to monitor tissues, and main-
tain homeostasis, cellular communication and immune
surveillance.6,7 They also participate in developmental pro-
cesses during embryogenesis.8-11 Upon inflammation,
whether induced by infection or injury, MФ are recruited
in large numbers from circulating monocytes to the tissue
and are often loosely classified as pro- or anti-inflamma-
tory. Previously, based on the actions of interferon-gamma
(IFN-c) and interleukin (IL)-4 on MФ activation and with
analogy to the Th1/2 T-cell subsets, MФ were divided into
two subtypes: ‘M1’ MФ, ‘classically activated’ by IFN-c;
and ‘M2’ MФ, ‘alternatively activated’ by type 2 anti-in-
flammatory cytokines such as IL-10. Those two subtypes
of MФ exhibit distinct metabolic function, the ‘M1’ hav-
ing an anaerobic profile, based on glycolysis and produc-
tion of nitric oxide (NO), whereas the ‘M2’ MФ have an
aerobic one, based on oxidative phosphorylation and pro-
duction of arginase.12-14 However, with current knowledge
on MФ origin, diversity and significant plasticity,15,16 the
acceptance of this dogma has diminished. Recent cutting-
edge technological developments such as single-cell RNA
sequencing (scRNAseq), advanced animal genetic modifi-
cation and intravital microscopy17-20 have allowed for a
greater appreciation of cellular diversity than previously
acknowledged. MФ not only have impressive variability in
their gene expression but they are also phenotypically
plastic, allowing them to adapt to their environment and
ensure appropriate responses. Tissue-specific transcrip-
tional programmes, instigated by local signals, enable phe-
notypic specialization in discrete microenvironmental
niches controlled by differential transcription factor
usage.21,22 Dysfunction of MФ behaviour or phenotype
has been associated with the development of many condi-
tions such as neurodegeneration, arthritis, chronic inflam-
mation, atherosclerosis and cancer,23,24 and the
identification of distinct subpopulations of MФ may be
key in disease understanding and treatment.25-27
All MФ rely on specific cytokine availability for survival,
proliferation and phenotype, including macrophage col-
ony-stimulating factor (M-CSF), granulocyte–macrophage
CSF (GM-CSF), IL-34 and transforming growth factor
beta 1 (TGF-b1), as single factor or in combination.6,28-30
MФ programming strongly depends on the environment,
which profoundly affects the cells at a transcriptomic and
epigenetic level.21,22,31 MФ also demonstrate remarkable
immune memory or ‘trained immunity’ capacities32-35
based on epigenetic modification following stimulation
and long-term priming or ‘imprinting’, as seen with apop-
totic cell recognition leading to a relatively stable tolerant
state.36-38 This immune memory appears critical during
transplant, when monocytes and MФ acquire specific
memory to major histocompatibility class I (MHCI).39
However, once isolated for ex vivo study, the characteristic
gene signature of tissue-resident MФ, including epigenetic
modification,22,40,41 is often lost, indicating the need to
explore their function and reprogramme them preferen-
tially in vivo, or with the in vivo context considered.
The aim of this review was to have a broad overview of
current research and possible treatments directed at MФ
in a selection of disease contexts. We have confined the
focus to specific organs and conditions detailed below,
purely as exemplars of the kinds of approaches that are
being considered. However, the potential for MФ target-
ing should not be considered restricted to the provided
examples.
Methods to reprogramme macrophages
MФ exhibit a high degree of plasticity in response to envi-
ronmental signals, many of which are tissue- and context-
specific. This results in a variety of MФ subtypes with dif-
ferent origins, which may play distinct roles in human dis-
ease and potentially provide unique opportunities for
targeted therapies.26,27,42 Before considering detailed
examples of therapeutic approaches in specific tissue and
disease contexts, we briefly introduce some common
methods used to reprogramme MФ, from conventional
approaches, such as targeted antibody treatments and
small molecule drugs to cutting-edge technology of gene
expression modification using viral vectors, artificial DNA
carriers, naked DNA and cell therapy (Figure 1).
Targeted antibody treatments are among the easiest and
most efficient methods to target not only MФ surface
receptors involved in the regulation of immune responses43
but also circulating cytokines/growth factors, preventing
their interaction.44 As a result, antibodies can alter MФ
activation status. However, this technique is mostly sys-
temic and can lead to numerous off-target effects.
Gene therapy aims to alter specific gene expression by
inserting genetic material into the target cell. Free nucleic
acids can be directly injected in vivo. While this is gener-
ally considered safe,45 detection by MФ can induce
inflammatory signalling. Although possibly advantageous
when reprogramming MФ into pro-inflammatory pheno-
types, it may counter anti-inflammatory states and raises
concern of off-target effects. Free nucleic acids also lack
cell-targeting specificity, an issue that can be solved by
attachment to carrier molecules, such as coupling to pep-
tides directly targeting MФ cell surface receptors.46
Nucleic acids can also be introduced using modified
viral vectors that lack the genes necessary for replication.
Lentiviral vectors stably integrate genetic material into the
host cell genome, while adenoviruses and adeno-associ-
ated viruses (AAVs) only cause transient gene expression.
Despite their high efficacy, viral vectors are associated
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with significant disadvantages: from a manufacturing per-
spective, viral vector production is costly and requires
specific safety measurements.47 From a clinical point of
view, random lentiviral RNA insertion into the genome
could cause tumour suppressor gene disruption triggering
malignancy.48 Also, viral vectors bear the risk of poten-
tially high immunogenicity.49,50 Adenoviruses’ triggering
of immune responses could, however, be exploited for the















































Figure 1. Summary of macrophage manipulation techniques for therapeutic purpose. These strategies can directly be applied in vivo, as well as
in vitro followed by adaptive transfer of manipulated MФ. Free nucleic acids (1) can be manufactured easily and are very successfully used in
some tissues including lungs and skeletal muscle. However, they lack MФ specificity and are rapidly cleared from the environment, mostly by cir-
culating enzymes and kidney. Viral vectors (2) can be employed to deliver nucleic acids, preventing clearance from the system. Depending on the
type of vector, gene manipulation can be long term (lentivirus) or transient (adenovirus). Viral vectors are highly efficient and can be modified
to improve MФ targeting. However, they do entail safety considerations for patients and manufacturing staff. Free small molecules and cytokines
(3) are known to act on MФ polarization. They are easy to administer but prone to degradation. They are also often not MФ specific and can
cause off-target effects and toxicity. Encapsulation of nucleic acids, small molecules and cytokines into nanovectors (4) prolongs their half-life in
the organism, while surface modifications (4b) allow targeting of specific cell types. Antibodies (5) can manipulate MФ polarization by directly
binding Fc or other cell surface receptors. While they are generally safe, high doses are often required for therapeutic efficacy translating into high
costs
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Another option for delivery of nucleic acids are non-
immunogenic nanoparticles (<100 nm), and organic (e.g.
liposome, polymers) or inorganic (e.g. gold, silica) parti-
cles widely used in clinical applications51 that are readily
ingested by MФ. Different types of nanovectors vary in
their advantages in clinical applications52 and can inher-
ently favour polarization towards either end of the MФ
activation spectrum.53
The use of nanoparticles in not restricted to nucleic
acid delivery. MФ can also be targeted with compounds
acting on signalling pathways to promote polarization
such as cyclooxygenase-2 inhibitors,54 receptor tyrosine
kinase inhibitors55 and histone deacetylase (HDAC) inhi-
bitors,56 as well as small molecule Toll-like receptor
(TLR) agonists57 and possibly cytokines.58 Free small
molecules can be associated with systemic side effects,
while unprotected molecules and cytokines are relatively
unstable in vivo.59 Such limitations can be overcome by
encapsulation into nanovectors.60,61 In general, nanoparti-
cles are well tolerated, small enough to cross physiological
barriers including the blood–brain barrier (BBB) and
easily modified to allow cell-targeted delivery. They do,
however, need to be carefully manufactured considering
possible toxicity associated with different materials and
delivery routes, as well as inflammatory responses associ-
ated with uptake by MФ.62
Blood and bone marrow-derived MФ (BMDM) can be
reprogrammed ex vivo by the same aforementioned meth-
ods and adoptively transferred to individuals. This may
help alleviate some of the off-target limitations of directly
targeting MФ in vivo.63 To retain polarization stability,
MФ can be genetically engineered ex vivo to over- or
under-express factors associated with polarization pheno-
types. An intriguing option was proposed by Shields and
colleagues: ex vivo attachment of IFN-c-loaded phagocy-
tosis-resistant ‘backpacks’ to BMDM enabled slow release
of IFN-c in vivo, allowing injected cells to maintain a
pro-inflammatory phenotype while simultaneously polar-
izing tumour-infiltrating MФ.64
The type of protocol used for therapeutic intervention
will depend on the tissue, MФ subtype and pathology to
be treated. Recently, a first-in-human phase 1 dose–esca-
lation trial confirmed the safety of autologous MФ ther-
apy in end-stage liver disease, which was well tolerated
and is currently undergoing efficacy measures in an ongo-
ing phase 2 randomized controlled trial.65
Tissue-specific consideration in macrophage
reprogramming
Cardiac macrophages
Mouse cardiac MФ are composed of four different sub-
sets, distinguishable by their cell surface expression of
typical markers such as MHCII, Ly6C, CCR2, CD11c,
MerTK, CD206 and CD64, and are derived from yolk
sac and fetal liver.66 Their self-renewal capacity decreases
with age, and they are thought to be gradually replen-
ished by monocyte-derived MФ over time.67 Cardiac
MФ play important roles in tissue homeostasis, angio-
genesis and vascular remodelling during embryogenesis,
as well as in the action potential propagation by being
electronically coupled with cardiomyocytes.68-70 During
inflammation or following injury such as myocardial
infarction (MI), resident cardiac MФ become activated
and high numbers of monocyte-derived MФ are
recruited to the injured site where their heterogeneity is
thought to impact MI outcome.71-73 Recruited cardiac
MФ participate in all phases of MI, from the first acute
inflammatory wave to the reparative phase and the pro-
motion of angiogenesis and muscle regeneration.74,75 The
repair after MI is associated with scar formation and
fibrosis, decreasing cardiac functionality.76 Interestingly,
the resident cardiac MФ seem to limit adverse remod-
elling77 and Gata6+ pericardial MФ have recently been
shown to enter the site of injury and prevent fibrosis.78
MI is a leading cause of death worldwide.79 Clinical tri-
als mainly focus on decreasing systemic inflammation by
suppressing the immune system and inflammation with
corticosteroid,80 methotrexate (phase 3, completed and
recruiting) or blocking pro-inflammatory molecules such
as IL-6 (tocilizumab, phase 2, active) and IL-1b (Ana-
kinra, completed81). However, the use of broad-range
immunosuppressors is questionable, as a controlled first
phase of inflammation has been shown to be essential to
tissue regeneration.82 In this line, recent work has shown
that a located injury such as MI not only modifies the
local MФ pool, but also affects the number and molecu-
lar signature of off-site MФ throughout the organism
(liver, lung and kidney),83 placing the effect of systemic
drugs in an even more central question. Recent research
focusing on the modulation of cardiac MФ phenotype
and activity in animal models shows promising results
encouraging further human clinical trials. Using
nanoparticle-delivered siRNA, Courties et al. successfully
silenced interferon regulatory factor 5 (IRF5) in cardiac
MФ in a mouse model of MI, which improved healing.84
Similarly, the targeting of miRNA-21 in cardiac MФ
with nanoparticles containing mimics (intravenously
injected) or adenovirus particles overexpressing miR-21
(intramyocardially injected) reduced inflammation, fibro-
sis and cardiac dysfunction.85,86 Finally, the intramyocar-
dial transplantation of in vitro M-CSF- and IL-4-primed
‘reparative’ MФ following MI in mice showed beneficial
effects over transplantation of non-primed bone marrow
mononuclear cells.87 While human assays to modify MФ
in vivo has been less prominent, recent work explored
the MФ heterogeneity and identified at least two subsets
(CCR2+ and CCR2-) present in human heart which are
essential for tissue function.88
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Macrophages in the central nervous system
Resident myeloid cells in the central nervous system
(CNS) include parenchymal microglia and different types
of non-parenchymal MФ.89 Additionally, inflammatory
conditions can trigger the influx of monocyte-derived
MФ90 through disruption of the BBB. Under physiologi-
cal conditions, this layer of endothelial cells restricts the
crossing of cells and compounds into the CNS as previ-
ously reviewed.91 Both dysregulated resident and infiltrat-
ing MФ have been linked to the pathophysiology of
several neurological disorders including Alzheimer’s dis-
ease (AD),92,93 multiple sclerosis (MS)94 and amyotrophic
lateral sclerosis (ALS).95 Currently, no cure exists for
those conditions and potential preventative and early
treatment options face the difficulty of drug delivery.
Multiple sclerosis
MS is an autoimmune, demyelinating disease of the brain
and spinal cord. It affects young adults causing progres-
sive neurological deterioration with common symptoms
including numbness, burning sensations, visual impair-
ment, loss of balance, bladder dysfunction, fatigue and
depression.96 While the aetiology of MS is incompletely
understood, it is believed that CNS-infiltrating pro-in-
flammatory phagocytes are key drivers in tissue destruc-
tion.94 Indeed, in MS patients such cells have been found
to express reduced levels of SHP-1 causing increased acti-
vation of STAT1, STAT6 and NF-jB.97 This was associ-
ated with a pro-inflammatory phenotype characterized by
elevated proteinases including ADAM8, which could dis-
rupt the BBB and contribute to demyelination, as well as
increased molecules associated with antigen presentation
and costimulation.98 This view is supported by studies of
experimental autoimmune encephalomyelitis (EAE), the
murine model for MS.99 Depletion of infiltrating phago-
cytes protected mice form axonal damage,100 while block-
ing microglial release of nitrite and pro-inflammatory
chemokines and cytokines significantly reduced clinical
signs in the EAE model.101 The polarization of microglia
by molecular control of cytokines and costimulatory
molecules by nuclear receptor has been shown to be
essential for the onset and development of EAE.102 EAE
has limitations concerning translation to human disease
but does still play an important role in drug develop-
ment.103
Glatiramer acetate (GA) is a polymer approved for the
treatment of relapsing–remitting MS. While its mode of
action is attributed to T-cell manipulation, GA also
increases microglial phagocytic activity and IL-10 produc-
tion while decreasing TNF in vitro.104 GA likely does not
cross the BBB on its own. However, it can be taken up
by dendritic cells (DCs) and released in the CNS, with
GA uptake promoting trans-endothelial migration of
DCs.105 Alternatively, GA could enter the CNS when the
BBB is disrupted in active MS lesions. Studies report GA-
mediated reductions in relapse rates;106 however, it is still
unclear whether its effect on microglia contributes to this
and whether GA actually slows disease progression.107 As
GM-CSF has been implicated in disease induction in the
EAE model, MOR103, a monoclonal antibody (mAb)
directed against GM-CSF, has been tested in MS patients
and was found to be well tolerated, although no assess-
ment regarding efficacy was conducted at this stage
(NCT01517282).
While infiltrating pro-inflammatory phagocytes are
potentially detrimental in MS, microglial production of
pro-inflammatory factors, especially TNF, might support
remyelination,108 calling for a specific targeting of periph-
eral MФ. Indeed, preventing peripheral MФ entry into
the CNS was beneficial in EAE.109
Therapeutics aiming to interfere with peripheral MФ
need to be carefully considered to not affect microglia
populations. In EAE, scRNAseq recently identified eight
different monocyte subsets, one of which expressing
CXCL10+ was associated with a pathogenic gene signa-
ture. This subset had also been observed in other inflam-
matory models such as pathogen infection, and its
depletion in EAE was associated with clinical improve-
ment.110 Whether and how this finding translates into the
human context remains to be investigated.
Alzheimer’s disease
AD is a chronic neurodegenerative disorder associated
with CNS inflammation and the main cause of dementia.
Genome-wide association studies have uncovered a vari-
ety of loci increasing susceptibility to the development of
late-onset Alzheimer’s disease, many of which are associ-
ated with immunity.93 In addition, rare coding variants,
such as that of triggering receptor expressed on myeloid
cells 2 (TREM2), have strongly been linked to increased
risk of developing AD.111 In line with this, in a murine
AD model expressing a TREM2 risk variant (R47H), anti-
human TREM2 mAb increased microglial proliferation,
reduced neuroinflammation and was associated with cog-
nitive benefits.112 The same antibody was well tolerated in
a phase I clinical trial (NCT03635047).
Activated microglia are thought protective early in dis-
ease but over time become dysfunctional causing inflam-
matory injury.113 Importantly, scRNAseq identified
distinct microglia subsets in AD, including a type associ-
ated with neuroprotection and increased phagocytosis
also found in a mouse model of ALS.25
An important regulator in microglial differentiation is
the M-CSF receptor (M-CSFR): depending on the murine
model and dose of inhibitor used, inhibition of M-CSFR
signalling resulted in blockade of microglial prolifera-
tion114,115 or microglial depletion116 inducing an anti-
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inflammatory state and cognitive improvements not asso-
ciated with alterations in amyloid plaques. Together, these
and other studies suggest M-CSFR inhibition as a viable
option for clinical trials. Importantly, M-CSFR expression
is not restricted to microglia but important for all macro-
phages. In line with this, M-CSFR inhibition was shown
to also affect circulating and tissue-resident macrophages
and lymphocytes in other organs in a mouse model.117 In
this paper, the M-CSFR inhibitor PLX5622 was adminis-
tered through diet. While not investigated by the authors,
it is likely that such a method of drug delivery would also
affect the gut microbiome. Considering the link between
intestinal dysbiosis and neurodegeneration,118 such a
method could affect treatment outcomes and a more
localized way of drug delivery, potentially by intranasal119
or direct intraventricular/intrathecal administration,120
could minimize off-target effects.
Amyotrophic lateral sclerosis
ALS is characterized by motoneuron degeneration typi-
cally causing paralysis and death within five years of diag-
nosis. In murine models, the number of resident
microglia increases throughout disease progression con-
comitant with a switch from an anti- to a pro-inflamma-
tory phenotype.121 Simultaneously, peripheral monocytes
from ALS patients have been suggested to be more readily
activated into pro-inflammatory phenotypes compared
with those of healthy individuals, further driving neuroin-
flammation after CNS infiltration.122
Vascular endothelial growth factor (VEGF) has been
suggested to play a neuroprotective role by reducing
motor neuron death through downregulation of pro-in-
flammatory cytokine production.123 Intrathecal injection
of adeno-associated virus containing VEGF expressing
plasmid induced VEGF expression in motor neurons in a
mouse model of ALS. This prolonged survival of the mice
by two modes of action: increasing anti-apoptotic factors
such as Bcl-2 and decreasing pro-apoptotic ones such as
Bax, caspase-3 and caspase-9 in neurons and a switch in
the inflammation balance (reduction in the pro-inflamma-
tory TNF, IL-1b and CD68 while increase in anti-inflam-
matory TGF-b released by microglia).124 Unfortunately,
phase II clinical trials for intracerebroventricular adminis-
tration of the common splicing isoform VEGF165 were
terminated due to a lack of favourable benefit–risk ratio
(NCT01384162).
The involvement of pro-inflammatory MФ and micro-
glia in the pathophysiology of neuroinflammatory condi-
tions strongly suggests the targeting of CNS myeloid cells
for re-education as a treatment option. However, to date
no agent designed to manipulate MФ activation states in
the CNS has been approved for the treatment of a neuro-
logical condition. This is partly due to poor animal mod-
els, which do not fully mimic human pathophysiology. It
is essential to understand the heterogeneity of myeloid
populations and individual contributions to neurological
pathologies in the CNS, to specifically target disease-asso-
ciated cell types. Imaging mass cytometry is already used
to characterize key players in neurological diseases by
applying antibodies to post-mortem sample.125 Addition-
ally, scRNAseq of human microglia from brain autopsy
samples could also uncover cell-specific targets for inter-
vention that could aid the development of therapeutics.
With potential targets being discovered, it is vital to also
reconsider options for drug delivery: compounds deliv-
ered systemically can eventually reach the brain but will
also affect cells in other tissues and organs. In particular,
in the case of macrophage manipulation, many receptors
and targets are shared by different tissue-resident macro-
phage populations making it difficult to prevent off-target
effects. This issue could be overcome by exploring intrac-
erebral,126 interstitial127 or intranasal128 delivery methods.
Liver macrophages
The murine liver comprises two distinct populations of
tissue-resident MФ, the Kupffer cells (KCs) that occupy
the sinusoidal vascular space, and the phenotypically
distinct liver capsular MФ, which reside in the hepatic
capsule.129 Additionally, the liver may also contain mono-
cyte-derived and peritoneal MФ,86 which are recruited
following inflammatory events or injury.130-132 Liver MФ
heterogeneity was recently reviewed.130,131 In mice, fetal
liver monocytic precursors give rise to embryonic KCs,
which at steady-state maintain the KC pool through self-
renewal, independent of BM-derived progenitors.1,133,134
In contrast, liver capsular MФ arise entirely from adult
circulating monocytes.129 More recently however, BM-
derived monocytes were shown to populate the KC niche
during postnatal liver development, contributing signifi-
cantly to the adult KC population.135 Following the loss
of KCs after infection,136 or experimental deple-
tion,135,137,138 the KC pool is repopulated through prolif-
eration of surviving KCs, as well as the recruitment and
differentiation of blood monocytes into KCs (mo-KCs).
These mo-KCs were shown to be highly functionally and
transcriptionally homologous to their embryonic counter-
parts135 after 30 days post-depletion, although other stud-
ies have shown that embryonically derived KCs may
exhibit some phenotypic and functional differences to
their monocyte-derived counterparts.137,139 The replenish-
ment of the depleted KC niche by either mechanism how-
ever, appears to be context-dependent. Indeed, in an
acute liver injury model, the depleted KC niche was
replenished through proliferation of the surviving KCs
without input from circulating monocytes.140 Similar to
the development and maintenance of other tissue-resident
MФ populations, recent studies have highlighted the criti-
cal role of transcription factors in governing KC
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development and identity, with the loss of inhibitor of
DNA 3 (ID3)141 or liver X receptor-alpha (LXR-a)142
resulting in KC deficiency in mice. Two recent studies in
mice demonstrated that liver-derived signals orchestrate
monocyte recruitment143 and initiate and maintain KC
identity through the induction of lineage-determining fac-
tors including ID3 and LXR-a by acting on pre-existing
but poised enhancers143,144. Additionally, leveraging of
scRNAseq technology for profiling human liver MФ has
revealed distinct subpopulations of KCs with discrete gene
expression signatures26,145-147, but our understanding of
their biology is still restricted compared with mouse liver
MФ.
Liver MФ play a key role in the pathogenesis of acute
and chronic liver diseases, including acute liver failure,
alcoholic liver disease, non-alcoholic fatty liver disease
(NAFLD), viral hepatitis and hepatocellular carcinoma.
They are also critically required for the restoration of tis-
sue homeostasis and resolution of liver disease.148 These
seemingly contrasting roles for liver MФ highlight the
importance to identify and understand the relative contri-
butions that distinct subsets have in disease progression,
as well as tissue repair, to help the development of
improved-targeted therapeutics, as well as the definition
of biomarkers indicating either disease progression or
regression (for a recent review, see Ref 131).
A recent study described a subset of Trem2hi MФ
enriched in mouse models of non-alcoholic steatohepati-
tis (NASH), as well as in human NASH livers, correlating
with disease severity.149 Interestingly, in a diet-induced
mouse model of NASH, KC identity was significantly
altered by the NASH diet. NASH-induced changes in KC
enhancers and gene expression were driven by activator
protein 1 and early growth response protein 1 inducing a
scar-associated MФ phenotype, with increased expression
of both Trem2 and Cd9.150 Interestingly, an independent
study also identified a scar-associated TREM2+CD9+ sub-
population of MФ in humans, which differentiate from
circulating monocytes and expand during liver fibrosis.26
In another study, a subset of MФ (MerTK+HLA-DRhigh)
was reported to expand during the resolution phase of
acute liver disease, with a comparable population identi-
fied in mice during the resolution phase of an acute liver
injury model.151 Further studies are needed to fully define
liver MФ subsets and their contributions to disease pro-
gression, as well as in tissue repair and the restoration of
homeostasis. However, some approaches to target MФ in
liver disorders are already under investigation.
Glucocorticoid and antibody–drug conjugate
Glucocorticoid receptor signalling modulates inflamma-
tion in KCs, suggesting that glucocorticoid treatment
could serve as a potential MФ-directed treatment for liver
diseases.152 Liposomal delivery of dexamethasone was
shown to significantly reduce liver injury and fibrosis in
experimental models of both acute and chronic liver inju-
ries.153 Direct targeting of MФ with an antibody–drug
conjugate composed of dexamethasone linked to an anti-
body against CD163 (a scavenger receptor highly
expressed in KCs and infiltrating monocytes/MФ) was
shown to reduce inflammation, hepatocyte ballooning
and fibrosis in a mouse model of NASH, while having no
apparent systemic side effects.154
Cytokines modulation
The pro-inflammatory cytokine TNF plays a major part
in the development of steatosis, inflammation and fibro-
sis in NAFLD. KCs have been identified as the main cel-
lular source of TNF in mouse models of NAFLD.
Mannose-modified trimethyl chitosan–cysteine-conjugated
nanoparticles were used to deliver siRNA targeting TNF
to MФ and protected mice from inflammation-driven
liver damage and lethality in an acute liver injury
model.155
Gene expression modification
Oxidative stress and the associated damage have been sug-
gested to link obesity and liver disease. Recently, Azzimato
and colleagues156 showed that oxidative stress was triggered
by obesity in mouse and human livers. In parallel, nuclear
factor erythroid 2-related factor 2 (NRF2), a transcription
factor regulating the antioxidant response, was reduced,
leading to an impaired antioxidant response. miR-144 was
greatly upregulated in the liver of obese and insulin-
resistant mice and humans and was shown to target NRF2.
Consequently, delivery of an antagomiR targeting miR-144
expression to MФ in vivo with glucan-encapsulated RNA
interference particle technology increased NRF2 protein
levels, reduced oxidative stress and improved hepatic meta-
bolism in insulin-resistant mice.
Small molecule inhibitors
Galectin-3 is a pleiotropic protein highly expressed by
MФ in the liver and upregulated in models of liver dis-
ease.157,158 Galectin-3 deficiency in mice was protective in
a concanavalin A-induced liver injury model, reducing
pro-inflammatory cytokines, as well as attenuating fibro-
sis.159 Similarly, pharmacological inhibition of Galectin-3
in liver injury models significantly reduced fibrosis and
led to a reversal in cirrhosis and is now under evaluation
for NASH in clinical trials.157,158
The dual CCR2/CCR5 inhibitor cenicriviroc was shown
to reduce monocyte recruitment and liver injury in an
acute liver failure model,160 as well as ameliorating hep-
atic inflammation and fibrosis in experimental models of
NASH,161 and is also currently under evaluation in
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clinical trials for the treatment of liver fibrosis in NASH
(NCT03059446 and NCT03028740).162
Adoptive transfer
In an experimental model of acute liver injury, adoptive
transfer of ex vivo IL-4/IL-13-polarized BMDM rapidly
reduced liver injury and several mediators of inflamma-
tion.163 Of note, the adoptive transfer of primary human-
polarized monocyte-derived MФ partially recapitulated
the therapeutic effect observed with polarized mouse
BMDM in the same mouse model.163 Similarly, injection
of BMDM or embryonic stem cell-derived MФ reduced
both fibrosis and improved liver regeneration in a hepatic
injury and fibrosis model.164,165 Clinical trials in humans
have demonstrated the safety of administration of large
and frequent infusions of autologous MФ. A recent first-
in-human trial evaluated the safety of a single peripheral
infusion of autologous MФ in end-stage liver disease,
which was well tolerated and led to a reduction in clinical
scoring, and is currently undergoing efficacy measures in
an ongoing phase 2 randomized controlled trial.65 How-
ever, this study did not determine whether the infused
MФ migrated to and engrafted in the liver. Previous
studies in mice, as well as a case study in humans, suggest
that the administration via peripheral or central veins
MФ traffic from the pulmonary vasculature via the blood
before engrafting in the liver and spleen.164,166-168 Signifi-
cant challenges remain for the adoption of autologous
MФ therapies, such as their scalability, as well ensuring
that engrafted cells maintain the intended phenotype,
which can be greatly impacted by the tissue microenvi-
ronment.
Macrophages in arthritis
Rheumatoid arthritis (RA) is a chronic, systemic inflam-
matory autoimmune disorder that primarily affects syn-
ovial joints, leading to irreversible bone and cartilage
destruction. Multiple studies have implicated monocytes
and MФ in the initiation and progression of RA.169 MФ
are the most abundant immune cell and are a source of
pro-inflammatory cytokines associated with RA pathogen-
esis including TNF, IL-6 and IL-1b,170 as well as chemo-
attractants and metalloproteinases. Conversely, synovial
tissue MФ in healthy and RA patients in sustained remis-
sion suggest that MФ have a fundamental role in main-
taining and/or reinstating synovial homeostasis.171,172 In a
murine model of sterile inflammatory arthritis, non-clas-
sical Ly6C- but not Ly6C+ monocytes were reported to be
crucial for the initiation of arthritis, while tissue-resident
synovial MФ restricted the development of arthritis.173
Murine synovial lining CX3CR1+ MФ form an immuno-
logical barrier in the lining layer of the synovium of
healthy joints.174 Depleting them in a mouse model of
arthritis disrupted barrier function and accelerated the
onset and magnitude of arthritis, whereas depletion of
CSF1R+ monocytes and MФ expedited the resolution of
inflammation. Interestingly, comparison of scRNAseq
data with human data sets from RA patients revealed sig-
nificant overlap, suggesting cells similar to synovial lining
MФ may also exist in humans.174 A recent study
described synovial MФ subsets enriched in active RA
(MerTK- CD206-) or sustained remission (MerTK+
CD206+), which are thought to contribute to RA patho-
genesis or remission through the production of pro-in-
flammatory cytokines or lipid mediators, respectively.175
Similarly, IL1B+ pro-inflammatory monocytes were
enriched in synovial tissue from patients with RA,
whereas NUPR1+ monocytes were inversely correlated
with tissue inflammation.176 Another study recently iden-
tified HBEGF+ inflammatory MФ enriched in the human
RA tissues,177 which promote synovial fibroblast invasive-
ness in an epidermal growth factor receptor (EGFR)-de-
pendent manner. Interestingly, a previous study showed
that EGFR inhibition reduced the severity of established
RA in mice.178 Collectively, these studies demonstrate that
distinct monocyte and MФ subsets have defined roles in
RA. Strategies are currently being developed to target MФ
and improve RA pathology.
Cytokines
Several lines of evidence suggest that MФ and GM-CSF
strongly influence the development and progression of
RA.179,180 In patients with RA, GM-CSF is elevated in
plasma, synovial fluid and synovial tissues, while adminis-
tration of recombinant GM-CSF has been reported to
exacerbated RA disease activity.181 Depletion of GM-CSF
or blockade of GM-CSFRa in a mouse model of RA sig-
nificantly reduced the number of MФ in the inflamed
synovium, decreased synovial inflammation and joint
destruction.182,183 Therapeutic antibodies targeting GM-
CSF and its receptor have been developed and evaluated
in clinical trials.181,184 Collectively, these studies have
shown that treatment is associated with rapid and sus-
tained improvements in measures of RA disease out-
comes, as well as being well tolerated in safety studies.185
Of note, a phase III clinical trial is currently ongoing
evaluating otilimab, a fully human anti-GM-CSF mono-
clonal antibody, in RA patients who have had an inade-
quate response to disease-modifying anti-rheumatic drugs
and/or Janus kinase inhibitors (NCT04134728).
Gene therapy
In the collagen-induced arthritis (CIA) mouse model,
Kong and colleagues identified three key pro-resolving
factors that were elevated in mouse synovial tissues dur-
ing the resolution phase of CIA.186 Among them, tyrosine
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3-monooxygenase/tryptophan 5-monooxygenase activa-
tion protein zeta (Ywhaz) was also shown to be elevated
in rat synovial tissue in a CIA model during the resolu-
tion phase compared with the peak phase, as well as in
RA patients who responded well to treatment with anti-
rheumatic drugs. Ywhaz is highly expressed in Tregs and
MФ and is one of the most common proteins found in
exosomes187 from Tregs, although no data were shown
for MФ in this study. Interestingly, treatment of thiogly-
collate-elicited peritoneal MФ with recombinant Ywhaz
reduced the expression of Tnf and Il6, while enhancing
Il10 expression.186 Furthermore, siRNA knockdown of
Ywhaz or treatment with an anti-Ywhaz antibody
enhanced the expression of Tnf and Il6 following LPS
stimulation, supporting a role of Ywhaz in modulating
pro-inflammatory cytokine production in MФ.186 Intra-
articular delivery of adenovirus expressing Ywhaz sup-
pressed the production of pro-inflammatory cytokines
and significantly reduced synovial inflammation and joint
destruction in mice.186 Ywhaz is a member of the 14-3-3
protein family, which modulate the activity of binding
partners by controlling protein localization, stability, con-
formation and activity mainly through phosphoserine/
threonine motifs.188 Previous studies have suggested that
Ywhaz can modulate the activity of forkhead box tran-
scription factor family O 3 (FOXO3), a transcription fac-
tor regulating the expression of cytokines,189 and
tristetraprolin (TTP),190 which regulates cytokine produc-
tion by destabilizing target mRNA molecules.191 However,
further studies are needed to understand how Ywhaz reg-
ulates the production of cytokines and the subsequent
resolution of arthritis. In arthritic rats, MФ phenotype
has been manipulated in vivo by tuftsin-modified
nanoparticle-mediated delivery of plasmid encoding IL-
10, leading to a significant reduction in pro-inflammatory
cytokine production, diminishing inflammation and pre-
venting the progression of joint damage.192
Tumour-associated macrophages
Cancers are heterogeneous tissues with tumour-infiltrat-
ing immune cells playing key roles in disease progres-
sion.193 Tumour-associated macrophages (TAMs) are
major components of the immune cells infiltrating solid
tumours. They are a heterogeneous population often
coexpressing pro- and anti-inflammatory markers.194
While pro-inflammatory functions could aid tumour cell
elimination,195 immune-suppressive TAMs are linked to
worse prognosis due to their contribution to tumour
growth and metastasis.196,197 TAMs repolarization to pro-
duce inflammatory mediators is currently being evaluated
in a number of clinical trials, examples of which are sum-
marized in Table 1.198-206 Several strategies to target
TAMs have been adopted, and we will describe common
ones below.
Receptor targeting
Just as in other tissues, the M-CSFR axis is an attractive
target in the tumour context: in many pre-clinical mod-
els, the use of M-CSFR inhibitors is associated with MФ
depletion and tumour regression in a T-cell-dependent
manner.207 However, blocking M-CSFR signalling in
murine proneural glioblastoma multiforme (PGM) and
hepatocellular carcinoma caused tumour regression with-
out TAM depletion, with persisting TAMs associated with
functional alterations.208,209 M-CSFR signalling can be
blocked by the use of antibodies targeting either M-CSF
or its receptor. While in some clinical trials antibody
treatment achieved disease stabilization,210 other studies
report TAM reductions without anti-tumour activity.211
Another option is the use of small molecule inhibitors
acting on the receptor tyrosine kinase domain (e.g.
PLX3397, BLZ945). Those inhibitors also interfere with
other receptors expressed in myeloid and tumour cells,
which could enhance their efficacy. As it has been shown
in a PGM model that tumours can acquire resistance to
BLZ945-mediated inhibition,212 the combination of M-
CSFR inhibitors with other immune- or chemotherapeu-
tic agents could be beneficial and is being evaluated in
clinical trials.
TLRs are involved in immune surveillance, and their
agonists can drive pro-inflammatory mediator release.213
Imiquimod (TLR7 agonist) is already approved for topi-
cal therapy in squamous and basal cell carcinoma, and
clinical trials are ongoing for several other TLR agonists.
Imiquimod’s mechanism of action likely affects not only
MФ but also dendritic cells and neutrophils.214 in vivo,
many TLR agonists have short half-lives, and some free
agonists have been associated with toxicity. Such issues
could be prevented by encapsulation into nanovectors.
While no such strategies are currently in clinical trials,
murine models support the efficacy and safety of resiqui-
mod-loaded nanoparticles61 and ferumoxytol-linked Poly
(I:C).215
Another example of receptor targeting exploits CD40, a
costimulatory molecule expressed on the surface of mye-
loid cells and B cells, with key roles in immune regula-
tion.216 Ligation with an agonist CD40 mAb triggered T-
cell-dependent anti-tumour immunity in murine models
of pancreatic ductal adenocarcinoma (PDAC) associated
with increased MHCII, CD80 and CD86 expression on
MФ and elevated serum levels of IL-12 and TNF.204
Depletion of MФ in this context prevented tumour
regression. In a clinical trial, CD40 mAb combined with
chemotherapy showed a trend of increased overall sur-
vival, even though the sample size was too small (n = 21)
for conclusive results.204 Several other clinical trials that
investigate the effect of targeting CD40 in different types
of tumours have already been summarized.217 While some
of these therapeutics are associated with positive tumour
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TLR7 Phase II NCT00821964 Complete Pathologic clinical response in
714% of patients
Advanced breast cancer200

















NCT02394132 Recruiting - Complex lentigo maligna
Imiquimod TLR7 Phase
IV
NCT01161888 Complete No results available Lentigo malignant of the
face
Resiquimod TLR7/8 Phase I/
II
NCT01676831 Complete Significant improvements of
treated lesions in 75% of patients,




852A TLR7 Phase I NCT00095160 Complete No results available Refractory solid organ
tumours
852A TLR7 Phase II NCT00319748 Complete Evidence of immune activation as




852A TLR7 Phase II NCT00189332 Complete No results available Metastatic cutaneous
melanoma
Imo-2055 TLR9 Phase II NCT00729053 Complete Treatment-emergent adverse events













CD40 Phase I NCT00711191 Complete Partial response in 4/21 patients,
stable diseases in 11/21 patients
Advanced cancer of the
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Vorinostat, gefitinib HDAC Phase I NCT02151721 Unknown - EGFR mutant lung cancer
IPI-549 alone and
with nivolumab




PI3Kc Phase II NCT03961698 Recruiting - Breast cancer, renal cell
carcinoma
IPI-549 PI3Kc Phase II NCT03795610 Recruiting - Locally advanced
HPV + and HPV- head
















NCT02829723 Recruiting - Advanced solid tumours
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outcomes, MФ-specific effects of treatment are generally
not investigated.
In a novel particle-based strategy, Shields and col-
leagues injected MФ equipped with ‘backpacks’ of
biodegradable polymers loaded with IFN-c into mice
bearing 4T1 tumours; they showed that ex vivo-polarized
MФ carrying these backpacks were able to not only main-
tain a pro-inflammatory phenotype in the tumour
microenvironment, but also induce the same phenotype
in resident TAMs, associated with reduced tumour
growth, lung metastasis and improved survival.64 As back-
packs could also be filled with cytokines promoting anti-
inflammatory polarization, such an approach could be
useful in other disease contexts.
Intracellular pathway targeting
TAMs can also be targeted with compounds that interfere
with internal signalling, including modifications of
nucleic acids, cellular kinases or HDAC.
Vorinostat, a small molecule inhibitor of HDAC, is
approved for cutaneous T-cell lymphoma due to its
growth-inhibiting effect on tumour cells.218 Vorinostat
also affects TAMs in murine models: encapsulating
vorinostat and a chemotherapeutic drug within liposomes
that target both non-small-cell lung cancer cells and
CD206-expressing MФ suppressed tumour growth via the
upregulation of iNOS, CD86 and TNF while downregu-
lating CD206, arginase and IL-10 in MФ.219
Another internal target for influencing MФ signalling is
PI3Kc, a phosphoinositide 3-kinases subunit mainly
expressed by myeloid cells. In a murine model of PDAC,
PI3Kc blockade with the PI3Kc/d inhibitor TG100-115
reduced MФ expression of Arginase1, TGF-ß and IL-10 and
increased IL-12 and IFN-c.220 This induced tumour suppres-
sion and prevented metastasis. MФ-specific effects were repli-
cated in a clinical trial of the selective PI3Kc inhibitor IPI-
549 as monotherapy and in combination with chemotherapy,
although the study is still ongoing and no results regarding
survival and tumour regression are available yet.221
In mouse models of ovarian cancer, melanoma and
glioblastoma, nanoparticle-mediated delivery of in vitro-
transcribed mRNAs encoding IRF5 together with its acti-
vating kinase IKKb increased pro-inflammatory myeloid
cells and caused tumour clearance in some animals.222
Similar results were found with nanoparticles delivering
siRNA targeting growth factors including VEGF and pla-
cental growth factor, which reduced MФ CD206 expres-
sion and IL-10 production while increasing IL-12 and
IFN-y in tumour tissues.223 Recently, siRNA-loaded
nanoparticle mediated silencing of signal transducer and
activator of transcription 3 and hypoxia-inducible factor
1 a prevented TAM-mediated angiogenesis and decreased
tumour size.224 In vitro, repolarization has also been
achieved with nanoparticle delivery of plasmid DNA
encoding the IL-12 gene225 and with overexpression of
microRNA-155 in triple negative breast cancer TAMs.226
Another approach delivers CRISPR-Cas9 gene editing
machinery into MФ: knock out of signal regulatory pro-
tein a, which engages CD47 on cancer cells and prevents
phagocytosis, significantly increased MФ targeting of
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TAMs re-education into pro-inflammatory phenotypes
can be beneficial to overcome tumour-induced immune
suppression. Reprogramming strategies can be combined
with existing immunotherapies, chemotherapy and radia-
tion, which has been shown to be successful in a variety
of clinical trials. Importantly, TAMs targeting should be
localized to cancerous areas to prevent systemic inflam-
mation, and only affect pro-tumoral MФ types. To
achieve this, further investigation into TAMs heterogene-
ity and careful design and delivery of potential therapeu-
tics are required.
Discussion
The recent development of individual cell-based technolo-
gies has led to an explosion of knowledge about MФ
ontogeny and diversity. The identification of their sub-
populations in homeostatic and disordered contexts is a
constantly growing field that highlights a broad pheno-
typic repertoire consistent with the variety of stimuli they
are exposed to. Their impact on disease development is
still under intense investigation and seems to be subtype-
dependent. While some subsets are thought to directly
contribute to disease progression, others have been found
to be protective. However, most investigation is per-
formed in animal models and the translation of this to
human patients is often less clear.
Past approaches to MФ reprogramming did not appre-
ciate MФ heterogeneity and plasticity, and how microen-
vironmental niche influences the phenotype. Early
adoptive transfer studies had limited/no efficacy because
of the impact of the in vivo microenvironment on MФ
phenotype once transferred.228 Novel experimental ave-
nues, however, have succeeded in maintaining the pheno-
type of adoptively transferred cells despite environmental
factors.64 Other strategies have focused on direct in vivo
modulation of MФ phenotypes, also giving promising
results. While different approaches to MФ reprogram-
ming have been described, each is associated with pitfalls
and benefits influencing their utility for specific tissues.
Where possible, future therapeutic approaches should
consider tailoring of strategy towards a specific tissue
microenvironment, as well as a specific disease-associated
subset of cells, to improve efficacy and minimize off-
target effects.
As MФ reprogramming is a recent approach to ther-
apy, important questions still need to be answered: How
stably can different subsets of MФ be re-educated? Is
long-term reprogramming of long-lived resident MФ safe?
As MФ are in constant interaction with their environ-
ment and other immune cells, including other MФ sub-
types, will modifying one particular subtype have
secondary unintended impacts on the tissue? An alterna-
tive approach may be secondary targeting of MФ popula-
tions via manipulation of their environmental cues
through alteration of the communication between tissue
and MФ. This could be achieved by targeting the cells
that support MФ growth and/or polarization, for exam-
ple. Either way, it is clear that further growth in under-
standing of MФ phenotypic heterogeneity in a given
microenvironmental/disease context is required to appre-
ciate the potential of targeting the MФ in disease and
capitalize on the advances that have begun to be made in
this area.
Acknowledgments
P.R.T is a Wellcome Trust Investigator Award (107964/Z/
15/Z) and an MRC UK Dementia Research Institute Pro-
fessor. R.J.P was an employee of GlaxoSmithKline at the
time of writing. R.J.P is currently an employee of the
University of Cambridge.
Competing interest statement




1 Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resi-
dent macrophages self-maintain locally throughout adult life with minimal contribu-
tion from circulating monocytes. Immunity 2013;38:792–804.
2 Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immu-
nol. 2013;14:986–95.
3 Davies LC, Taylor PR. Tissue-resident macrophages: then and now. Immunology
2015;144:541–8.
4 Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis.
Immunity 2016;44:439–49.
5 Gordon S, Martinez-Pomares L. Physiological roles of macrophages. Pflugers Arch.
2017;469:365–74.
6 Kierdorf K, Prinz M, Geissmann F, Gomez PE. Development and function of tissue
resident macrophages in mice. Semin Immunol. 2015;27:369–78.
7 Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic
surveillants of brain parenchyma in vivo. Science 2005;308(5726):1314–8.
8 MichaelsonMD, Bieri PL,MehlerMF, XuH, Arezzo JC, Pollard JW, et al. CSF-1 deficiency
inmice results in abnormal braindevelopment.Development 1996;122:2661–72.
9 DeFalco T, Bhattacharya I, Williams AV, Sams DM, Capel B. Yolk-sac-derived macro-
phages regulate fetal testis vascularization and morphogenesis. Proc Natl Acad Sci U S
A. 2014;111:E2384–E2393.
10 Diez-Roux G, Argilla M, Makarenkova H, Ko K, Lang RA. Macrophages kill capillary
cells in G1 phase of the cell cycle during programmed vascular regression. Develop-
ment 1999;126:2141–7.
11 Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol.
2009;9:259–70.
12 Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the
Th1/Th2 paradigm. J Immunol. 2000;164:6166–73.
13 Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the
nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by
TH1 and TH2 cytokines. Eur J Immunol. 1995;25:1101–4.
14 Viola A, Munari F, Sanchez-Rodriguez R, Scolaro T, Castegna A. The metabolic signa-
ture of macrophage responses. Front Immunol. 2019;10:1462.
15 Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, et al.
Macrophage activation switching: an asset for the resolution of inflammation. Clin
Exp Immunol. 2005;142:481–9.
ª 2021 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 163, 128–144 139
16 Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-
based network analysis reveals a spectrum model of human macrophage activation.
Immunity 2014;40:274–88.
17 McArdle S, Mikulski Z, Ley K. Live cell imaging to understand monocyte, macro-
phage, and dendritic cell function in atherosclerosis. J Exp Med. 2016;213:1117–31.
18 Tay TL, Mai D, Dautzenberg J, Fernandez-Klett F, Lin G, Sagar, et al. A new fate
mapping system reveals context-dependent random or clonal expansion of microglia.
Nat Neurosci. 2017;20:793–803.
19 Li C, Menoret A, Farragher C, Ouyang Z, Bonin C, Holvoet P, Vella AT, Zhou B.
Single-cell transcriptomics–based MacSpectrum reveals macrophage activation signa-
tures in diseases. JCI Insight. 2019;4:10. http://doi.org/10.1172/jci.insight.126453
20 Bian Z, Gong Y, Huang T, Lee CZW, Bian L, Bai Z, et al. Deciphering human macro-
phage development at single-cell resolution. Nature 2020;582:571–6.
21 Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, et al. Tis-
sue-resident macrophage enhancer landscapes are shaped by the local microenviron-
ment. Cell 2014;159:1312–26.
22 Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, et al.
Environment drives selection and function of enhancers controlling tissue-specific
macrophage identities. Cell 2014;159:1327–40.
23 Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis
and disease. Nature 2013;496:445–55.
24 Schultze JL, Schmieder A, Goerdt S. Macrophage activation in human diseases. Semin
Immunol. 2015;27:249–56.
25 Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland
TK, et al. A unique microglia type associated with restricting development of Alzhei-
mer’s disease. Cell 2017;169:1276–90 e17.
26 Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT,
et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature
2019;575:512–8.
27 Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, et al.
Human tumor-associated macrophage and monocyte transcriptional landscapes reveal
cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell
2019;35:588–602 e10.
28 Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and
function by colony stimulating factors. Dev Comp Immunol. 2004;28:509–54.
29 Hamilton JA. GM-CSF-dependent inflammatory pathways. Front Immunol.
2019;10:2055.
30 Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev
Immunol. 2008;8:533–44.
31 T’Jonck W, Guilliams M, Bonnardel J. Niche signals and transcription factors involved
in tissue-resident macrophage development. Cell Immunol. 2018;330:43–53.
32 Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, et al. Epige-
netic programming of monocyte-to-macrophage differentiation and trained innate
immunity. Science 2014;345:1251086.
33 Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by
TLR-induced chromatin modifications. Nature. 2007;447:972–8.
34 Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E,
et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol.
2020;20:375–88.
35 Wendeln AC, Degenhardt K, Kaurani L, Gertig M, Ulas T, Jain G, et al. Innate
immune memory in the brain shapes neurological disease hallmarks. Nature
2018;556:332–8.
36 Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macro-
phages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine
production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and
PAF. J Clin Invest. 1998;101:890–8.
37 Weavers H, Evans IR, Martin P, Wood W. Corpse engulfment generates a molecular
memory that primes the macrophage inflammatory response. Cell 2016;165:1658–71.
38 Gordon S, Pluddemann A. Macrophage clearance of apoptotic cells: a critical assess-
ment. Front Immunol. 2018;9:127.
39 Dai H, Lan P, Zhao D, Abou-Daya K, Liu W, Chen W, et al. PIRs mediate innate
myeloid cell memory to nonself MHC molecules. Science 2020;368:1122–7.
40 Shemer A, Grozovski J, Tay TL, Tao J, Volaski A, Suss P, et al. Engrafted parenchymal
brain macrophages differ from microglia in transcriptome, chromatin landscape and
response to challenge. Nat Commun. 2018;9:5206.
41 Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA. Diverse
requirements for microglial survival, specification, and function revealed by defined-
medium cultures. Neuron 2017;94(4):759–73 e8.
42 Mould KJ, Jackson ND, Henson PM, Seibold M, Janssen WJ. Single cell RNA
sequencing identifies unique inflammatory airspace macrophage subsets. JCI Insight.
2019;4:5.http://dx.doi.org/10.1172/jci.insight.126556
43 Pellizzari G, Hoskin C, Crescioli S, Mele S, Gotovina J, Chiaruttini G, et al. IgE re-
programs alternatively-activated human macrophages towards pro-inflammatory anti-
tumoural states. EBioMedicine. 2019;43:67–81.
44 Degboe Y, Rauwel B, Baron M, Boyer JF, Ruyssen-Witrand A, Constantin A, et al.
Polarization of rheumatoid macrophages by TNF targeting through an IL-10/STAT3
mechanism. Front Immunol. 2019;10:3.
45 Herweijer H, Wolff JA. Progress and prospects: naked DNA gene transfer and therapy.
Gene Ther. 2003;10:453–8.
46 Kim SS, Ye C, Kumar P, Chiu I, Subramanya S, Wu H, et al. Targeted delivery of
siRNA to macrophages for anti-inflammatory treatment. Mol Ther. 2010;18:993–1001.
47 Collins DE, Reuter JD, Rush HG, Villano JS. Viral vector biosafety in laboratory ani-
mal research. Comp Med. 2017;67:215–21.
48 Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, et al. Efficacy of
gene therapy for X-linked severe combined immunodeficiency. N Engl J Med.
2010;363:355–64.
49 Gregory SM, Nazir SA, Metcalf JP. Implications of the innate immune response to
adenovirus and adenoviral vectors. Future Virol. 2011;6:357–74.
50 Annoni A, Gregori S, Naldini L, Cantore A. Modulation of immune responses in len-
tiviral vector-mediated gene transfer. Cell Immunol. 2019;342:103802.
51 Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med.
2019;4:e10143.
52 Hu G, Guo M, Xu J, Wu F, Fan J, Huang Q, et al. Nanoparticles targeting macro-
phages as potential clinical therapeutic agents against cancer and inflammation. Front
Immunol. 2019;10:1998.
53 Reichel D, Tripathi M, Perez JM. Biological effects of nanoparticles on macrophage
polarization in the tumor microenvironment. Nanotheranostics. 2019;3:66–88.
54 Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-Kawano R, Kanda K, et al.
COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to
M1 in ApcMin/+ mouse polyps. Carcinogenesis 2011;32:1333–9.
55 Myers KV, Amend SR, Pienta KJ. Targeting Tyro3, Axl and MerTK (TAM receptors):
implications for macrophages in the tumor microenvironment. Mol Cancer.
2019;18:94.
56 Moreira JD, Koch BEV, van Veen S, Walburg KV, Vrieling F, Guimaraes MPD, et al.
Functional inhibition of host histone deacetylases (HDACs) enhances in vitro and
in vivo anti-mycobacterial activity in human macrophages and in zebrafish. Front
Immunol. 2020;11:36.
57 Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. TLR7/8-
agonist-loaded nanoparticles promote the polarization of tumour-associated macro-
phages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2:578–88.
58 Shahbazi MA, Sedighi M, Bauleth-Ramos T, Kant K, Correia A, Poursina N, et al.
Targeted reinforcement of macrophage reprogramming toward M2 polarization by IL-
4-loaded hyaluronic acid particles. ACS Omega. 2018;3:18444–55.
59 Zidek Z, Anzenbacher P, Kmonickova E. Current status and challenges of cytokine
pharmacology. Br J Pharmacol. 2009;157:342–61.
60 Kwon D, Cha BG, Cho Y, Min J, Park EB, Kang SJ, et al. Extra-large pore meso-
porous silica nanoparticles for directing in vivo M2 macrophage polarization by deliv-
ering IL-4. Nano Lett. 2017;17:2747–56.
61 Thauvin C, Widmer J, Mottas I, Hocevar S, Allemann E, Bourquin C, et al. Develop-
ment of resiquimod-loaded modified PLA-based nanoparticles for cancer
immunotherapy: a kinetic study. Eur J Pharm Biopharm. 2019;139:253–61.
62 Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin
FH, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater
Res. 2019;23:20.
63 Parsa R, Andresen P, Gillett A, Mia S, Zhang XM, Mayans S, et al. Adoptive transfer
of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice. Dia-
betes 2012;61:2881–92.
64 Shields CWT, Evans MA, Wang LL, Baugh N, Iyer S, Wu D, et al. Cellular backpacks
for macrophage immunotherapy. Sci Adv. 2020;6:eaaz6579.
65 Moroni F, Dwyer BJ, Graham C, Pass C, Bailey L, Ritchie L, et al. Safety profile of
autologous macrophage therapy for liver cirrhosis. Nat Med. 2019;25:1560–5.
66 Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, et al. Embry-
onic and adult-derived resident cardiac macrophages are maintained through distinct
mechanisms at steady state and during inflammation. Immunity 2014;40:91–104.
67 Molawi K, Wolf Y, Kandalla PK, Favret J, Hagemeyer N, Frenzel K, et al. Progressive
replacement of embryo-derived cardiac macrophages with age. J Exp Med.
2014;211:2151–8.
68 Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, et al. Macrophages
facilitate electrical conduction in the heart. Cell 2017;169:510–22 e20.
69 Pinto AR, Paolicelli R, Salimova E, Gospocic J, Slonimsky E, Bilbao-Cortes D, et al.
An abundant tissue macrophage population in the adult murine heart with a distinct
alternatively-activated macrophage profile. PLoS One 2012;7:e36814.
ª 2021 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 163, 128–144140
V. M. T. Bart et al.
70 Leid J, Carrelha J, Boukarabila H, Epelman S, Jacobsen SE, Lavine KJ. Primitive
embryonic macrophages are required for coronary development and maturation. Circ
Res. 2016;118:1498–511.
71 Ruparelia N, Godec J, Lee R, Chai JT, Dall’Armellina E, McAndrew D, et al. Acute
myocardial infarction activates distinct inflammation and proliferation pathways in
circulating monocytes, prior to recruitment, and identified through conserved tran-
scriptional responses in mice and humans. Eur Heart J. 2015;36:1923–34.
72 Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T, et al. Impact
of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage
in patients with primary acute myocardial infarction. J Am Coll Cardiol. 2009;54:130–
8.
73 Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, et al. Differential con-
tribution of monocytes to heart macrophages in steady-state and after myocardial
infarction. Circ Res. 2014;115:284–95.
74 Frodermann V, Nahrendorf M. Macrophages and cardiovascular health. Physiol Rev.
2018;98:2523–69.
75 Mouton AJ, DeLeon-Pennell KY, Rivera Gonzalez OJ, Flynn ER, Freeman TC, Saucer-
man JJ, et al. Mapping macrophage polarization over the myocardial infarction time
continuum. Basic Res Cardiol. 2018;113:26.
76 Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibrob-
last awakens. Circ Res. 2016;118:1021–40.
77 Dick SA, Macklin JA, Nejat S, Momen A, Clemente-Casares X, Althagafi MG, et al.
Self-renewing resident cardiac macrophages limit adverse remodeling following
myocardial infarction. Nat Immunol. 2019;20:29–39.
78 Deniset JF, Belke D, Lee WY, Jorch SK, Deppermann C, Hassanabad AF, et al. Gata6
(+) pericardial cavity macrophages relocate to the injured heart and prevent cardiac
fibrosis. Immunity 2019;51:131–40 e5.
79 Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al.
Heart disease and stroke statistics-2018 update: a report from the American Heart
Association. Circulation 2018;137:e67–e492.
80 Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid
treatment in acute myocardial infarction. Am J Cardiol. 2003;91:1055–9.
81 Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, et al. Inter-
leukin-1 blockade inhibits the acute inflammatory response in patients with ST-seg-
ment-elevation myocardial infarction. J Am Heart Assoc. 2020;9:e014941.
82 Liu J, Wang H, Li J. Inflammation and inflammatory cells in myocardial infarction
and reperfusion injury: a double-edged sword. Clin Med Insights Cardiol. 2016;10:79–
84.
83 Hoyer FF, Naxerova K, Schloss MJ, Hulsmans M, Nair AV, Dutta P, et al. Tissue-
specific macrophage responses to remote injury impact the outcome of subsequent
local immune challenge. Immunity 2019;51:899–914 e7.
84 Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, et al. in vivo silencing
of the transcription factor IRF5 reprograms the macrophage phenotype and improves
infarct healing. J Am Coll Cardiol. 2014;63:1556–66.
85 Bejerano T, Etzion S, Elyagon S, Etzion Y, Cohen S. Nanoparticle delivery of miRNA-
21 mimic to cardiac macrophages improves myocardial remodeling after myocardial
infarction. Nano Lett. 2018;18:5885–91.
86 Yang L, Wang B, Zhou Q, Wang Y, Liu X, Liu Z, et al. MicroRNA-21 prevents exces-
sive inflammation and cardiac dysfunction after myocardial infarction through target-
ing KBTBD7. Cell Death Dis. 2018;9:769.
87 Podaru MN, Fields L, Kainuma S, Ichihara Y, Hussain M, Ito T, et al. Reparative
macrophage transplantation for myocardial repair: a refinement of bone marrow
mononuclear cell-based therapy. Basic Res Cardiol. 2019;114:34.
88 Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, et al.
The human heart contains distinct macrophage subsets with divergent origins and
functions. Nat Med. 2018;24:1234–45.
89 Lopez-Atalaya JP, Askew KE, Sierra A, Gomez-Nicola D. Development and mainte-
nance of the brain’s immune toolkit: Microglia and non-parenchymal brain macro-
phages. Dev Neurobiol. 2018;78:561–79.
90 Garre JM, Yang G. Contributions of monocytes to nervous system disorders. J Mol
Med (Berl). 2018;96:873–83.
91 Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC
Neurol. 2009;9(Suppl 1):S3.
92 Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G, et al. Micro-
glial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer’s disease.
Nat Neurosci. 2010;13:411–3.
93 International Genomics of Alzheimer’s Disease C. Convergent genetic and expression
data implicate immunity in Alzheimer’s disease. Alzheimer’s Dementia. 2015;11:658–
71.
94 Chu F, Shi M, Zheng C, Shen D, Zhu J, Zheng X, et al. The roles of macrophages
and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis. J
Neuroimmunol. 2018;318:1–7.
95 Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mecha-
nisms and emerging therapies. Lancet Neurol. 2019;18:211–20.
96 Goldenberg MM. Multiple sclerosis review. P T. 2012;37:175–84.
97 Christophi GP, Panos M, Hudson CA, Christophi RL, Gruber RC, Mersich AT, et al.
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and
enhanced inflammatory phenotype. Lab Invest. 2009;89:742–59.
98 Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of
’homeostatic’ microglia and patterns of their activation in active multiple sclerosis.
Brain 2017;140:1900–13.
99 Locatelli G, Theodorou D, Kendirli A, Jordao MJC, Staszewski O, Phulphagar K, et al.
Mononuclear phagocytes locally specify and adapt their phenotype in a multiple scle-
rosis model. Nat Neurosci. 2018;21:1196–208.
100 Moreno MA, Burns T, Yao P, Miers L, Pleasure D, Soulika AM. Therapeutic depletion
of monocyte-derived cells protects from long-term axonal loss in experimental
autoimmune encephalomyelitis. J Neuroimmunol. 2016;290:36–46.
101 Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hovelmeyer N, et al. Experi-
mental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med.
2005;11:146–52.
102 Rothe T, Ipseiz N, Faas M, Lang S, Perez-Branguli F, Metzger D, et al. The nuclear receptor
Nr4a1 acts as a microglia rheostat and serves as a therapeutic target in autoimmune-driven
central nervous system inflammation. J Immunol. 2017;198:3878–85.
103 Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune
encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol.
2011;164:1079–106.
104 Pul R, Moharregh-Khiabani D, Skuljec J, Skripuletz T, Garde N, Voss EV, et al. Glatiramer
acetate modulates TNF-alpha and IL-10 secretion in microglia and promotes their phago-
cytic activity. JNeuroimmunePharmacol. 2011;6:381–8.
105 Liu J, JohnsonTV, Lin J, Ramirez SH, Bronich TK,Caplan S, et al. T cell independentmech-
anism for copolymer-1-inducedneuroprotection.Eur J Immunol. 2007;37:3143–54.
106 Wynn DR. Enduring clinical value of copaxone(R) (Glatiramer Acetate) in multiple
sclerosis after 20 years of use. Mult Scler Int. 2019;2019:7151685.
107 Boster A, Bartoszek MP, O’Connell C, Pitt D, Racke M. Efficacy, safety, and cost-ef-
fectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple scle-
rosis. Ther Adv Neurol Disord. 2011;4:319–32.
108 Olah M, Amor S, Brouwer N, Vinet J, Eggen B, Biber K, et al. Identification of a
microglia phenotype supportive of remyelination. Glia 2012;60:306–21.
109 Getts DR, Terry RL, Getts MT, Deffrasnes C, Muller M, van Vreden C, et al. Thera-
peutic inflammatory monocyte modulation using immune-modifying microparticles.
Sci Transl Med. 2014;6:219ra7.
110 Giladi A, Wagner LK, Li H, Dorr D, Medaglia C, Paul F, et al. Cxcl10(+) monocytes
define a pathogenic subset in the central nervous system during autoimmune neuroin-
flammation. Nat Immunol. 2020;21:525–34.
111 Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2
variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27.
112 Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, et al. Anti-human
TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s dis-
ease model. J Exp Med. 2020;217:e20200785.
113 Solito E, Sastre M. Microglia function in Alzheimer’s disease. Front Pharmacol.
2012;3:14.
114 Olmos-Alonso A, Schetters ST, Sri S, Askew K, Mancuso R, Vargas-Caballero M, et al.
Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the
progression of Alzheimer’s-like pathology. Brain 2016;139(Pt 3):891–907.
115 Dagher NN, Najafi AR, Kayala KM, Elmore MR, White TE, Medeiros R, et al. Col-
ony-stimulating factor 1 receptor inhibition prevents microglial plaque association and
improves cognition in 3xTg-AD mice. J Neuroinflammation. 2015;12:139.
116 Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MR, Blurton-Jones M, et al.
Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating
amyloid-beta pathology. Brain 2016;139(Pt 4):1265–81.
117 Lei F, Cui N, Zhou C, Chodosh J, Vavvas DG, Paschalis EI. CSF1R inhibition by a
small-molecule inhibitor is not microglia specific; affecting hematopoiesis and the
function of macrophages. Proc Natl Acad Sci USA. 2020;117:23336–8.
118 Quigley EMM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol
Neurosci Rep. 2017;17:94.
119 Erdo F, Bors LA, Farkas D, Bajza A, Gizurarson S. Evaluation of intranasal delivery
route of drug administration for brain targeting. Brain Res Bull. 2018;143:155–70.
120 Atkinson AJ Jr. Intracerebroventricular drug administration. Transl Clin Pharmacol.
2017;25:117–24.
121 Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D’Ambrosi N. The dual
role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neu-
rosci. 2017;9:242.
122 Du Y, Zhao W, Thonhoff JR, Wang J, Wen S, Appel SH. Increased activation ability
of monocytes from ALS patients. Exp Neurol. 2020;328:113259.
ª 2021 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 163, 128–144 141
123 Wang H, Wang Y, Li D, Liu Z, Zhao Z, Han D, et al. VEGF inhibits the inflammation
in spinal cord injury through activation of autophagy. Biochem Biophys Res Commun.
2015;464:453–8.
124 Wang Y, Duan W, Wang W, Di W, Liu Y, Liu Y, et al. scAAV9-VEGF prolongs the
survival of transgenic ALS mice by promoting activation of M2 microglia and the
PI3K/Akt pathway. Brain Res. 2016;1648(Pt A):1–10.
125 Ramaglia V, Sheikh-Mohamed S, Legg K, Park C, Rojas OL, Zandee S, et al. Multi-
plexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry.
Elife. 2019;8:e48051.
126 Yurek D, Hasselrot U, Sesenoglu-Laird O, Padegimas L, Cooper M. Intracerebral
injections of DNA nanoparticles encoding for a therapeutic gene provide partial neu-
roprotection in an animal model of neurodegeneration. Nanomedicine. 2017;13:2209–
17.
127 Hu N, Shi X, Zhang Q, Liu W, Zhu Y, Wang Y, et al. Special interstitial route can
transport nanoparticles to the brain bypassing the blood-brain barrier. Nano Research.
2019;12:2760–5.
128 Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C, Dao L, et al. Potential of nanopar-
ticulate drug delivery systems by intranasal administration. Curr Pharm Des.
2010;16:1644–53.
129 Sierro F, Evrard M, Rizzetto S, Melino M, Mitchell AJ, Florido M, et al. A liver capsu-
lar network of monocyte-derived macrophages restricts hepatic dissemination of
intraperitoneal bacteria by neutrophil recruitment. Immunity 2017;47:374–88 e6.
130 Bleriot C, Ginhoux F. Understanding the heterogeneity of resident liver macrophages.
Front Immunol. 2019;10:2694.
131 Guillot A, Tacke F. Liver macrophages: old dogmas and new insights. Hepatol Com-
mun. 2019;3:730–43.
132 Wang J, Kubes P. A reservoir of mature cavity macrophages that can rapidly invade
visceral organs to affect tissue repair. Cell 2016;165:668–78.
133 Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals
origins and dynamics of monocytes and tissue macrophages under homeostasis.
Immunity 2013;38:79–91.
134 Hoeffel G, Chen J, Lavin Y, Low D, Almeida FF, See P, et al. C-Myb(+) erythro-mye-
loid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages.
Immunity 2015;42:665–78.
135 Scott CL, Zheng F, De Baetselier P, Martens L, Saeys Y, De Prijck S, et al. Bone mar-
row-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells.
Nat Commun. 2016;7:10321.
136 Bleriot C, Dupuis T, Jouvion G, Eberl G, Disson O, Lecuit M. Liver-resident macro-
phage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated
tissue repair during bacterial infection. Immunity 2015;42:145–58.
137 Beattie L, Sawtell A, Mann J, Frame TCM, Teal B, de Labastida RF, et al. Bone mar-
row-derived and resident liver macrophages display unique transcriptomic signatures
but similar biological functions. J Hepatol. 2016;65:758–68.
138 David BA, Rezende RM, Antunes MM, Santos MM, Freitas Lopes MA, Diniz AB,
et al. Combination of mass cytometry and imaging analysis reveals origin, location,
and functional repopulation of liver myeloid cells in mice. Gastroenterology
2016;151:1176–91.
139 Soysa R, Lampert S, Yuen S, Douglass AN, Li W, Pfeffer K, et al. Fetal origin confers
radioresistance on liver macrophages via p21(cip1/WAF1). J Hepatol. 2019;71:553–62.
140 Zigmond E, Samia-Grinberg S, Pasmanik-Chor M, Brazowski E, Shibolet O, Halpern
Z, et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display
different ontogeny and functions in acute liver injury. J Immunol. 2014;193:344–53.
141 Mass E, Ballesteros I, Farlik M, Halbritter F, Gunther P, Crozet L, et al. Specification
of tissue-resident macrophages during organogenesis. Science 2016;353:aaf4238.
142 Scott CL, T’Jonck W, Martens L, Todorov H, Sichien D, Soen B, et al. The transcrip-
tion factor ZEB2 is required to maintain the tissue-specific identities of macrophages.
Immunity 2018;49(2):312–25 e5.
143 Bonnardel J, T’Jonck W, Gaublomme D, Browaeys R, Scott CL, Martens L, et al. Stel-
late cells, hepatocytes, and endothelial cells imprint the kupffer cell identity on mono-
cytes colonizing the liver macrophage niche. Immunity 2019;51:638–54 e9.
144 Sakai M, Troutman TD, Seidman JS, Ouyang Z, Spann NJ, Abe Y, et al. Liver-derived
signals sequentially reprogram myeloid enhancers to initiate and maintain kupffer cell
identity. Immunity 2019;51:655–70 e8.
145 MacParland SA, Liu JC, Ma XZ, Innes BT, Bartczak AM, Gage BK, et al. Single cell
RNA sequencing of human liver reveals distinct intrahepatic macrophage populations.
Nat Commun. 2018;9:4383.
146 Aizarani N, Saviano A, Sagar ML, Durand S, Herman JS, et al. A human liver cell atlas
reveals heterogeneity and epithelial progenitors. Nature 2019;572:199–204.
147 Zhao J, Zhang S, Liu Y, He X, Qu M, Xu G, et al. Single-cell RNA sequencing reveals
the heterogeneity of liver-resident immune cells in human. Cell Discov. 2020;6:22.
148 Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al.
Selective depletion of macrophages reveals distinct, opposing roles during liver injury
and repair. J Clin Invest. 2005;115:56–65.
149 Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, et al. Landscape of intercellular
crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis.
Mol Cell. 2019;75:644–60 e5.
150 Seidman JS, Troutman TD, Sakai M, Gola A, Spann NJ, Bennett H, et al. Niche-speci-
fic reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalco-
holic steatohepatitis. Immunity 2020;52:1057–74 e7.
151 Triantafyllou E, Pop OT, Possamai LA, Wilhelm A, Liaskou E, Singanayagam A, et al.
MerTK expressing hepatic macrophages promote the resolution of inflammation in
acute liver failure. Gut 2018;67:333–47.
152 Robert O, Boujedidi H, Bigorgne A, Ferrere G, Voican CS, Vettorazzi S, et al.
Decreased expression of the glucocorticoid receptor-GILZ pathway in Kupffer cells
promotes liver inflammation in obese mice. J Hepatol. 2016;64:916–24.
153 Bartneck M, Scheyda KM, Warzecha KT, Rizzo LY, Hittatiya K, Luedde T, et al. Fluo-
rescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflamma-
tory liver diseases. Biomaterials 2015;37:367–82.
154 Svendsen P, Graversen JH, Etzerodt A, Hager H, Roge R, Gronbaek H, et al. Anti-
body-directed glucocorticoid targeting to CD163 in M2-type macrophages attenuates
fructose-induced liver inflammatory changes. Mol Ther Methods Clin Dev. 2017;4:50–
61.
155 He C, Yin L, Tang C, Yin C. Multifunctional polymeric nanoparticles for oral delivery
of TNF-alpha siRNA to macrophages. Biomaterials 2013;34:2843–54.
156 Azzimato V, Jager J, Chen P, Morgantini C, Levi L, Barreby E, et al. Liver macro-
phages inhibit the endogenous antioxidant response in obesity-associated insulin resis-
tance. Sci Transl Med. 2020;12:eaaw9709.
157 Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, et al. Regression of fibro-
sis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced
liver disease. PLoS One 2013;8:e75361.
158 Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibi-
tors. PLoS One 2013;8:e83481.
159 Volarevic V, Milovanovic M, Ljujic B, Pejnovic N, Arsenijevic N, Nilsson U, et al.
Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology
2012;55:1954–64.
160 Mossanen JC, Krenkel O, Ergen C, Govaere O, Liepelt A, Puengel T, et al. Chemokine
(C-C motif) receptor 2-positive monocytes aggravate the early phase of acetamino-
phen-induced acute liver injury. Hepatology 2016;64:1667–82.
161 Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, et al.
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis
and liver fibrosis. Hepatology 2018;67:1270–83.
162 Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM,
Yuan J, et al. Cenicriviroc for the treatment of liver fibrosis in adults with nonalco-
holic steatohepatitis: AURORA Phase 3 study design. Contemp Clin Trials.
2020;89:105922.
163 Starkey Lewis P, Campana L, Aleksieva N, Cartwright JA, Mackinnon A, O’Duibhir E,
et al. Alternatively activated macrophages promote resolution of necrosis following
acute liver injury. J Hepatol. 2020;73:349–60.
164 Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S, et al.
Macrophage therapy for murine liver fibrosis recruits host effector cells improving
fibrosis, regeneration, and function. Hepatology 2011;53:2003–15.
165 Haideri SS, McKinnon AC, Taylor AH, Kirkwood P, Starkey Lewis PJ, O’Duibhir E,
et al. Injection of embryonic stem cell derived macrophages ameliorates fibrosis in a
murine model of liver injury. NPJ Regen Med. 2017;2:14.
166 Hutchinson JA, Riquelme P, Sawitzki B, Tomiuk S, Miqueu P, Zuhayra M, et al. Cut-
ting Edge: Immunological consequences and trafficking of human regulatory macro-
phages administered to renal transplant recipients. J Immunol. 2011;187:2072–8.
167 Bird TG, Lu WY, Boulter L, Gordon-Keylock S, Ridgway RA, Williams MJ, et al. Bone
marrow injection stimulates hepatic ductular reactions in the absence of injury via
macrophage-mediated TWEAK signaling. Proc Natl Acad Sci U S A. 2013;110:6542–7.
168 Sharkey J, Starkey Lewis PJ, Barrow M, Alwahsh SM, Noble J, Livingstone E, et al.
Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient
iron-labeling in macrophages for magnetic resonance-based detection in vivo.
Cytotherapy. 2017;19:555–69.
169 Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of
rheumatoid arthritis. Nat Rev Rheumatol. 2016;12:472–85.
170 McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the
immunological landscape. Nat Rev Rheumatol. 2016;12(1):63–8.
171 Smith MD. The normal synovium. Open Rheumatol J. 2011;5:100–6.
172 Alivernini S, Tolusso B, Petricca L, Bui L, Di Sante G, Peluso G, et al. Synovial fea-
tures of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultra-
sound remission differ under anti-TNF therapy: a clue to interpret different chances
of relapse after clinical remission? Ann Rheum Dis. 2017;76:1228–36.
173 Misharin AV, Cuda CM, Saber R, Turner JD, Gierut AK, Haines GK 3rd, et al. Non-
classical Ly6C(-) monocytes drive the development of inflammatory arthritis in mice.
Cell Rep. 2014;9:591–604.
ª 2021 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 163, 128–144142
V. M. T. Bart et al.
174 Culemann S, Gruneboom A, Nicolas-Avila JA, Weidner D, Lammle KF, Rothe T, et al.
Locally renewing resident synovial macrophages provide a protective barrier for the
joint. Nature 2019;572:670–5.
175 Alivernini S, MacDonald L, Elmesmari A, Finlay S, Tolusso B, Gigante MR, et al. Dis-
tinct synovial tissue macrophage subsets regulate inflammation and remission in
rheumatoid arthritis. Nat Med 2020;26:1295–306.
176 Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, et al. Defining inflam-
matory cell states in rheumatoid arthritis joint synovial tissues by integrating single-
cell transcriptomics and mass cytometry. Nat Immunol. 2019;20:928–42.
177 Kuo D, Ding J, Cohn IS, Zhang F, Wei K, Rao DA, et al. HBEGF(+) macrophages
in rheumatoid arthritis induce fibroblast invasiveness. Sci Transl Med. 2019;11:
eaau8587.
178 Swanson CD, Akama-Garren EH, Stein EA, Petralia JD, Ruiz PJ, Edalati A, et al. Inhi-
bition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-in-
duced arthritis. J Immunol. 2012;188:3513–21.
179 Cook AD, Pobjoy J, Steidl S, Durr M, Braine EL, Turner AL, et al. Granulocyte-
macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis
pain and disease development. Arthritis Res Ther. 2012;14:R199.
180 Hamilton JA. GM-CSF as a target in inflammatory/autoimmune disease: current evi-
dence and future therapeutic potential. Expert Rev Clin Immunol. 2015;11:457–65.
181 Hamilton JA, Cook AD, Tak PP. Anti-colony-stimulating factor therapies for inflam-
matory and autoimmune diseases. Nat Rev Drug Discov. 2016;16:53–70.
182 Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from
collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-defi-
cient mice. J Immunol. 1998;161:3639–44.
183 Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-in-
duced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating
factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis
Res. 2001;3:293–8.
184 Hamilton JA. GM-CSF in inflammation. J Exp Med. 2020;217:1.
185 Cook AD, Hamilton JA. Investigational therapies targeting the granulocyte macro-
phage colony-stimulating factor receptor-alpha in rheumatoid arthritis: focus on
mavrilimumab. Ther Adv Musculoskelet Dis. 2018;10:29–38.
186 Kong JS, Park JH, Yoo SA, Kim KM, Bae YJ, Park YJ, et al. Dynamic transcriptome
analysis unveils key proresolving factors of chronic inflammatory arthritis. J Clin
Invest. 2020;130:3974–86.
187 Mathivanan S, Simpson RJ. ExoCarta: a compendium of exosomal proteins and RNA.
Proteomics 2009;9:4997–5000.
188 Kaplan A, Bueno M, Fournier AE. Extracellular functions of 14-3-3 adaptor proteins.
Cell Signal. 2017;31:26–30.
189 Dobson M, Ramakrishnan G, Ma S, Kaplun L, Balan V, Fridman R, et al. Bimodal
regulation of FoxO3 by AKT and 14-3-3. Biochim Biophys Acta. 2011;1813:1453–64.
190 Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, et al. MK2-in-
duced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-
mRNA decay. EMBO J. 2004;23:1313–24.
191 Schaljo B, Kratochvill F, Gratz N, Sadzak I, Sauer I, Hammer M, et al. Tristetraprolin
is required for full anti-inflammatory response of murine macrophages to IL-10. J
Immunol. 2009;183:1197–206.
192 Jain S, Tran TH, Amiji M. Macrophage repolarization with targeted alginate nanopar-
ticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Bio-
materials 2015;61:162–77.
193 Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor
initiation to metastatic progression. Genes Dev. 2018;32:1267–84.
194 Helm O, Held-Feindt J, Grage-Griebenow E, Reiling N, Ungefroren H, Vogel I, et al.
Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by
which they impact on pancreatic tumorigenesis. Int J Cancer. 2014;135:843–61.
195 Bucana C, Hoyer LC, Hobbs B, Breesman S, McDaniel M, Hanna MG Jr. Morphologi-
cal evidence for the translocation of lysosomal organelles from cytotoxic macrophages
into the cytoplasm of tumor target cells. Cancer Res. 1976;36:4444–58.
196 Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages:
an accomplice in solid tumor progression. J Biomed Sci. 2019;26:78.
197 Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol
Immunol. 2015;12:1–4.
198 Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, et al. Topical
TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in
patients with breast cancer. Clin Cancer Res. 2012;18:6748–57.
199 Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, et al. Topical imi-
quimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical
trial. JAMA Oncol. 2017;3:969–73.
200 Pachman DR, Barton DL, Clayton AC, McGovern RM, Jefferies JA, Novotny PJ, et al.
Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am
J Obstet Gynecol. 2012;206:42 e1–7.
201 Grimm C, Polterauer S, Natter C, Rahhal J, Hefler L, Tempfer CB, et al. Treatment of
cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled
trial. Obstet Gynecol. 2012;120:152–9.
202 Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, et al. Topical resi-
quimod can induce disease regression and enhance T-cell effector functions in cuta-
neous T-cell lymphoma. Blood 2015;126:1452–61.
203 Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, et al. A phase
I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with
gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer
Res. 2013;19:6286–95.
204 Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al.
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in
mice and humans. Science 2011;331:1612–6.
205 Calvo A, Joensuu H, Sebastian M, Naing A, Bang Y-J, Martin M, et al. Phase Ib/II
study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients
(pts) with advanced tumors. J Clin Oncol 2018;36(15_suppl):3014.
206 Autio KA, Klebanoff CA, Schaer D, Kauh JS, Slovin SF, Blinder VS, et al. Phase 1
study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in
patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate
cancer (MCRPC). J Clin Oncol 2019;37(15_suppl):2548.
207 Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, et al. CSF1R inhibi-
tion delays cervical and mammary tumor growth in murine models by attenuating the
turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T
cells. Oncoimmunology. 2013;2:e26968.
208 Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al.
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat
Med. 2013;19:1264–72.
209 Ao JY, Zhu XD, Chai ZT, Cai H, Zhang YY, Zhang KZ, et al. Colony-stimulating fac-
tor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-
associated macrophages in hepatocellular carcinoma. Mol Cancer Ther. 2017;16:1544–
54.
210 Gomez-Roca CA, Cassier PA, Italiano A, Cannarile M, Ries C, Brillouet A, et al. Phase
I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic
solid tumors. J Clin Oncol 2015;33(15_suppl):3005.
211 Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D’Angelo
SP, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel
in patients with advanced/metastatic solid tumors reveals depletion of immunosup-
pressive M2-like macrophages. Ann Oncol. 2019;30:1381–92.
212 Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, et al. The
tumor microenvironment underlies acquired resistance to CSF-1R inhibition in glio-
mas. Science 2016;352:aad3018.
213 Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med.
2007;13:460–9.
214 Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol. 2007;157(Suppl
2):8–13.
215 Zhao J, Zhang Z, Xue Y, Wang G, Cheng Y, Pan Y, et al. Anti-tumor macrophages
activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist
poly (I : C) promote melanoma regression. Theranostics. 2018;8:6307–21.
216 van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2–17.
217 Piechutta M, Berghoff AS. New emerging targets in cancer immunotherapy: the role
of Cluster of Differentiation 40 (CD40/TNFR5). ESMO Open. 2019;4(Suppl 3):
e000510.
218 Bubna AK. Vorinostat-an overview. Indian J Dermatol. 2015;60:419.
219 Peng H, Chen B, Huang W, Tang Y, Jiang Y, Zhang W, et al. Reprogramming tumor-
associated macrophages to reverse EGFR(T790M) resistance by dual-targeting codeliv-
ery of gefitinib/vorinostat. Nano Lett. 2017;17:7684–90.
220 Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, et al.
Macrophage PI3Kgamma drives pancreatic ductal adenocarcinoma progression. Cancer
Discov. 2016;6:870–85.
221 Sullivan RJ, Hong DS, Tolcher AW, Patnaik A, Shapiro G, Chmielowski B, et al. Ini-
tial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent,
combined with nivolumab in advanced solid tumors. J Clin Oncol 2018;36(15_-
suppl):3013.
222 Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, et al. Genetic pro-
gramming of macrophages to perform anti-tumor functions using targeted mRNA
nanocarriers. Nat Commun. 2019;10:3974.
223 Song Y, Tang C, Yin C. Combination antitumor immunotherapy with VEGF and
PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-asso-
ciated macrophages and breast cancer cells. Biomaterials 2018;185:117–32.
224 Shobaki N, Sato Y, Suzuki Y, Okabe N, Harashima H. Manipulating the function of
tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer
immunotherapy. J Control Release. 2020;325:235–48.
ª 2021 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 163, 128–144 143
225 He XY, Liu BY, Xu C, Zhuo RX, Cheng SX. A multi-functional macrophage and
tumor targeting gene delivery system for the regulation of macrophage polarity and
reversal of cancer immunoresistance. Nanoscale. 2018;10:15578–87.
226 Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang CY, et al. Re-polarization of tumor-associ-
ated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol
Cell Biol. 2012;4:341–3.
227 Ray M, Lee YW, Hardie J, Mout R, Yesilbag Tonga G, Farkas ME, et al. CRISPRed
macrophages for cell-based cancer immunotherapy. Bioconjug Chem. 2018;29:445–50.
228 Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using
monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc
Biol. 1998;64:419–26.
ª 2021 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 163, 128–144144
V. M. T. Bart et al.
